T regulatory cell receptor (Treg receptor)

T regulatory cell (Treg) receptors represent a functional class of surface proteins, such as CD25 (IL2RA), CTLA-4, and GITR, that are essential for the suppressive activity and homeostasis of regulatory T cells (Nature Reviews Immunology, 2020). These receptors allow Tregs to maintain peripheral tolerance by inhibiting the activation and proliferation of autoreactive effector T cells (PubMed, 2018). In cancer, high expression of these receptors on intratumoral Tregs contributes to an immunosuppressive microenvironment that facilitates tumor evasion (Journal of Clinical Investigation, 2019). Therapeutic strategies often involve monoclonal antibodies like ipilimumab, which blocks CTLA-4 to enhance anti-tumor immunity, or basiliximab, which targets CD25 to prevent organ transplant rejection (StatPearls, 2023). Other emerging targets in this class include TIGIT and LAG-3, which are being investigated in combination with PD-1 inhibitors to improve clinical outcomes in oncology (NIH, 2022). The primary challenge in targeting these receptors is the risk of inducing severe immune-related adverse events (irAEs) due to the disruption of systemic immune balance (PubMed, 2021).

Other names

Regulatory T-cell receptorTreg surface markersCD25CTLA-4GITROX40LAG-3TIGITCCR4ICOS

Mechanisms include immune checkpoint inhibition, antibody-dependent cellular cytotoxicity (ADCC) mediated depletion of regulatory T cells, competitive inhibition of cytokine signaling (e.g., IL-2), and agonism of co-stimulatory pathways to enhance suppressive function.